The latest data point for Q1'26 shows challenging profitability for RXRX, with Gross Margin at -0.93%, Operating Margin at -19.86%, and Net Profit Margin at -18.16%, indicating ongoing operational losses despite some prior improvements in gross metrics. Over the period from Q2'23 to Q1'26, the chart reveals volatile trends across all margins, starting with deeply negative Operating and Net Profit Margins around -7% to -9% that slightly improved to -3.7% and -3.7% in Q3'24 before plummeting to -40.4% and -39.4% in Q4'24 due to apparent one-time pressures. Gross Margin exhibited a positive trajectory from 14.8% in Q2'23 to a peak of 53.7% in Q3'24, followed by sharp declines to -181.4% in Q4'24 and subsequent fluctuations, while Operating and Net Profit Margins remained consistently negative with no sustained recovery, highlighting persistent cost inefficiencies in this line chart analysis.